Posted by Michael Wonder on 06 Jul 2024
Summary of consultation to widen access to cancer medicines and treatments to prevent fungal infections
5 July 2024 - PHARMAC is proposing to widen access to two medicines for cancer and two medicines for prevention of fungal infections in people with weakened immune systems, subject to eligibility criteria.
The medicines are:
- Pembrolizumab (branded as Keytruda)
- Nivolumab (branded as Opdivo)
- Posaconazole (branded as Posaconazole Juno and Devatis)
- Voriconazole (branded as Vttack and Vfend)
